DaVita (NYSE:DVA) Insider Sells $3,210,402.00 in Stock

DaVita Inc. (NYSE:DVA) insider Kathleen Alyce Waters sold 15,405 shares of the business’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the sale, the insider directly owned 109,194 shares in the company, valued at $22,756,029.60. This trade represents a 12.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

DaVita Stock Up 0.9%

Shares of DVA traded up $1.78 during trading hours on Wednesday, reaching $210.76. 618,197 shares of the company traded hands, compared to its average volume of 973,431. The business has a fifty day moving average price of $178.66 and a 200-day moving average price of $147.52. The stock has a market capitalization of $13.53 billion, a P/E ratio of 19.55, a P/E/G ratio of 0.69 and a beta of 0.91. DaVita Inc. has a 12-month low of $101.00 and a 12-month high of $213.44.

DaVita (NYSE:DVA) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $2.87 earnings per share for the quarter, beating the consensus estimate of $2.33 by $0.54. The business had revenue of $3.42 billion for the quarter, compared to the consensus estimate of $3.36 billion. DaVita had a negative return on equity of 270.37% and a net margin of 5.65%.The company’s quarterly revenue was up 6.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.00 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, research analysts predict that DaVita Inc. will post 15.07 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. UBS Group upped their target price on DaVita from $190.00 to $235.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Barclays upped their price objective on shares of DaVita from $158.00 to $194.00 and gave the company an “equal weight” rating in a report on Thursday, May 7th. Truist Financial upped their price target on shares of DaVita from $158.00 to $205.00 and gave the company a “hold” rating in a report on Friday, May 8th. Wall Street Zen upgraded DaVita from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Finally, Zacks Research upgraded DaVita from a “hold” rating to a “strong-buy” rating in a research note on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $199.17.

Institutional Trading of DaVita

Hedge funds have recently added to or reduced their stakes in the company. Root Financial Partners LLC boosted its stake in shares of DaVita by 128.0% during the 1st quarter. Root Financial Partners LLC now owns 187 shares of the company’s stock worth $29,000 after acquiring an additional 105 shares in the last quarter. Elevation Wealth Partners LLC boosted its stake in shares of DaVita by 147.3% during the 4th quarter. Elevation Wealth Partners LLC now owns 277 shares of the company’s stock worth $31,000 after acquiring an additional 165 shares in the last quarter. Caitlin John LLC purchased a new position in DaVita during the fourth quarter worth approximately $34,000. Sankala Group LLC purchased a new position in DaVita during the fourth quarter worth approximately $39,000. Finally, Canada Pension Plan Investment Board purchased a new position in DaVita during the second quarter worth approximately $43,000. 90.12% of the stock is owned by hedge funds and other institutional investors.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.